ACSL4 and prostate neoplasm: Since E2F is the primary transcription factor (mainly E2F1) driven by RB1 loss to regulate ACSL4 expression in prostate cancer, they unveiled the control of ferroptosis through the RB/E2F/ACSL4 axis, emphasizing the potential therapeutic application of inducing ferroptosis for treating prostate tumor growth driven by RB1 loss.